Prostate Cancer - Results from #280

Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients. September 9, 2024

Development of prediction models based on risk scores for clinically significant prostate cancer on MRI/TRUS fusion biopsy. September 6, 2024

PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers. September 6, 2024

The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate. September 6, 2024

VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer. September 6, 2024

Estimated incidence of disruptions to event-free survival from non-metastatic cancers in New South Wales, Australia - a population-wide epidemiological study of linked cancer registry and treatment data. September 6, 2024

Comparison of Pathologist and Artificial Intelligence-based Grading for Prediction of Metastatic Outcomes After Radical Prostatectomy. September 6, 2024

The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions. September 5, 2024

A Multi-Institutional Study of MR/US Fusion Guided Nanoparticle Directed Focal Therapy for Prostate Ablation. September 5, 2024

Talazoparib for the treatment of prostate cancer. September 5, 2024

PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer. September 5, 2024

Pelvic Lymph Node Dissection: A Comparison Among Extraperitoneal Single-port and Transperitoneal Multiport Radical Prostatectomy-A Single-center Experience. September 5, 2024

The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer. September 5, 2024

The Proteogenomics of Prostate Cancer Radioresistance. September 5, 2024

Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis. September 4, 2024

Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis. September 4, 2024

A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease. September 4, 2024

Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes. September 4, 2024

Statin concentration in prostatic tissue is subtype- and dose-dependent. September 4, 2024

Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal Status. September 4, 2024

Page 15 of 1434